Among patients diagnosed with a hormone receptor-positive and epidermal growth factor receptor 2 (HER2) non-amplified BC (also referred to as ‘luminal-like’ BC subtype), approximately 20–30% will eventually develop distant relapse, leading to lethal disease. Here, ERBB2 is linked to breast cancer.